Regenxbio Inc expected to post a loss of $1.10 a share - Earnings Preview

Regenxbio

28/07/2025 12:12

Regenxbio Inc RGNX.OQ RGNX.O is expected to  show a rise in quarterly revenue when it reports  results on July 30 (estimated) for the period ending June 30 2025

The Rockville Maryland-based  company is expected to report a 26.1% increase in revenue to $28.113 million from $22.3 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Regenxbio Inc is for a loss of $1.10 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Regenxbio Inc is $31.50, about 71.6% above its last closing price of $8.96

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.53
0.48
0.12
Missed
-75.1
Dec. 31 2025
-1.24
-1.15
-1.01
Beat
11.9
Sep. 30 2024
-1.11
-1.12
-1.17
Missed
-4.3​
Jun. 30 2024
-1.30
-1.29
-1.05
Beat
18.7
​​Mar. 31 2024
-1.29
-1.26
-1.33
Missed
-5.6
Dec. 31 2023
-1.30
-1.27
-1.43
Missed
-12.5​
Sep. 30 2023
-1.56
-1.52
-1.41
Beat
7.1
Jun. 30 2023
-1.43
-1.38
-1.66
Missed
-19.9

This summary was machine generated July 28 at 11:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)